Barclays’s Accelerate Diagnostics AXDX Stock Holding History

Barclays’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,910	Closed	-$1.13M	–	6927
2018 Q3	$1.13M	Buy	+4,910	New	+$1.09M	﹤0.01%	3510
2018 Q1	–	Sell	-670	Closed	-$176K	–	7047
2017 Q4	$176K	Buy	+670	New	+$157K	﹤0.01%	4787

Other funds holding AXDX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cannell & Spears New York $5.62B AUM 41.25% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's AXDX Position: Q4 2024 in Review

Barclays sold out of Accelerate Diagnostics (AXDX) in Q4 2024, closing a stake of 100 shares — an estimated $171 sold.

Barclays first reported a position in AXDX in Q2 2013 and held it in 36 quarters. The position peaked at $1.54M in Q2 2019. 47 funds tracked by Wall St. Rank hold AXDX as of Q4 2024.

Barclays reported no remaining Accelerate Diagnostics position as of Q4 2024 after selling out during the quarter.
Barclays sold 100 Accelerate Diagnostics shares in Q4 2024, an estimated $171.
Barclays first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 36 quarters.
Barclays's Accelerate Diagnostics position peaked at $1.54M in Q2 2019.
47 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.